Odyssey Group International’s Planned Acquisition of Concussion Drug from Prevacus, Inc. Enhances Delivery Capabilities with Nasal Therapeutic

Odyssey Group International, Inc., a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce it is circulating a video to better define its drug candidate PRV-002, a therapeutic compound drug to treat concussion (mild traumatic brain injury (mTBI), from UF Innovate | Sid Martin Biotech alum Prevacus Inc. Odyssey is expected to acquire PRV-002 by the end of February.

The fast acting 5-minute nasal therapeutic delivery works through gene amplification and crosses into the brain to reduce inflammation, oxidative stress and swelling at the contusion site. The resulting animal data reduces headaches, improves memory, prevents balance impairment and prevents life-threatening increases in brain pressure.

View the video and read more about Odyssey Group International’s Planned Acquisition of Concussion Drug from Prevacus, Inc. Enhances Delivery Capabilities with Nasal Therapeutic.